Our findings reveal molecular insight into how the IR‐HER2/AKT/NF‐κB‐RNF126‐MRE11‐ATR/CHK1 pathway is activated and how DDR choices are determined in cells during DSBs, in turn providing innovative paradigms for the DNA damage response and therapeutic applications for cancer treatment. The gene discussed is ATR; the disease is cancer.